Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Yunfei Lv, Kuang Chen, Chunmei Yang, De Zhou, Juying Wei, Wanzhuo Xie, Gongqiang Wu, Jingcheng Zhang, Qin Pan, Jie Jin, Yanhong Tong, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 7253.

https://doi.org/10.1182/blood-2025-7253

Published: 2025

Journal Articles

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Xuewu Zhang, Yunfei Lv, Xiang Zhang, Xingnong Ye, Chunmei Yang, Juying Wei, De Zhou, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 3596.

https://doi.org/10.1182/blood-2025-3596

Published: 2025

Journal Articles

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Linjie Li, Beili Hu, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2025-1911

Published: 2025

Journal Articles

A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia

Huafeng Wang, Yile Zhou, Xiang Zhang, Liping Mao, Xia Li, Xingnong Ye, Mixue Xie, De Zhou, Xiudi Yang, Jian Huang, Wenjuan Yu, Juying Wei, Min Yang, Yinjun Lou, Yanhong Tong, Jie Jin

Blood (2025) 146 (Supplement 1): 3464.

https://doi.org/10.1182/blood-2025-3464

Published: 2025

Journal Articles

Azacytidine combined with CHOP regimen for the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma

Chunmei Yang, Chao Hu, Juying Wei, Liping Mao, Huafeng Wang, Liangshun You, De Zhou, Haitao Meng, Gaixiang Xu, Liya Ma, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2025-1859

Published: 2025

Journal Articles

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2025-1907

Published: 2025

Journal Articles

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

De Zhou, Xianbo Huang, Lixia Zhu, Xuelian Hu, Xiudi Yang, Mixue Xie, Xin Huang, Fang Yu, Juying Wei, Liya Ma, Jingjing Zhu, Shuqi Zhao, Wanzhuo Xie, Hongyan Tong, Jie Jin, Xiujin Ye

Blood (2025) 146 (3): 318–327.

https://doi.org/10.1182/blood.2024026139

Published: 2025

Includes: Supplemental data

Journal Articles

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Blood (2025) 146 (1): 76–88.

https://doi.org/10.1182/blood.2024027689

Published: 2025

Includes: Supplemental data

Journal Articles

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Xuewu Zhang, Yanan Zhu, Xiang Zhang, Xingnong Ye, Gaixiang Xu, Liya Ma, Yanling Ren, Liping Mao, Min Yang, Chunmei Yang, Juying Wei, Yinjun Lou, Wenyuan Mai, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2024-204442

Published: 2024

Journal Articles

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Haiyan Zhang, Xiang Zhang, Jinghan Wang, Xuewu Zhang, Yunfei Lv, Yanan Zhu, Juying Wei, Min Yang, Gaixiang Xu, Xingnong Ye, Yinjun Lou, Chunmei Yang, Haitao Meng, Wanzhuo Xie, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6468.

https://doi.org/10.1182/blood-2024-205687

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Ying Huang, Yanan Zhu, Xiang Zhang, Xuewu Zhang, Juying Wei, Xingnong Ye, Yinjun Lou, Min Yang, Chunmei Yang, Wanzhuo Xie, Haitao Meng, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2024-205842

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2024-201210

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2024-201190

Published: 2024

Journal Articles

Real-World Outcomes in Grade 3B Follicular Lymphoma and Composite Follicular Lymphoma with Diffuse Large B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study in China

Yufei Lv, Xiang Zhang, Yanan Zhu, Juying Wei, Xuewu Zhang, Xingnong Ye, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2024-202204

Published: 2024

Journal Articles

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Xuewu Zhang, Haitao Meng, Gaixiang Xu, Min Yang, Wanzhuo Xie, Juying Wei, Liya Ma, Xingnong Ye, Liping Mao, Wenyuan Mai, Chunmei Yang, Yanling Ren, Hongyan Tong, Yanan Zhu, Xiang Zhang, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6772.

https://doi.org/10.1182/blood-2024-203639

Published: 2024

Journal Articles

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Yanan Zhu, Yunfei Lv, Xingnong Ye, Juying Wei, Lixia Sheng, Ying Lin, Xiang Zhang, Xuewu Zhang, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2024-198711

Published: 2024

Journal Articles

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2024-200064

Published: 2024

Journal Articles

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2024-203722

Published: 2024

Journal Articles

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2024-209459

Published: 2024

Journal Articles

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Chunmei Yang, Liping Mao, Juying Wei, Wanzhuo Xie, Xingnong Ye, Min Yang, Jian Huang, De Zhou, Liya Ma, Yinjun Lou, Huafeng Wang, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6518.

https://doi.org/10.1182/blood-2024-202298

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia

Azacytidine combined with CHOP regimen for the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Real-World Outcomes in Grade 3B Follicular Lymphoma and Composite Follicular Lymphoma with Diffuse Large B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study in China

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only